Download PDF

1. Company Snapshot

1.a. Company Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.


The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease.PTC Therapeutics, Inc.has collaborations with F.


Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc.to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean.PTC Therapeutics, Inc.


was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Show Full description

1.b. Last Insights on PTCT

PTC Therapeutics' recent performance was driven by its robust Q3 results, with total revenue reaching $211 million and a strong launch of Sephience (sepiapterin) for phenylketonuria treatment. The company's quarterly earnings of $0.2 per share beat estimates, marking a significant turnaround. Additionally, the company's presentation at the Citi Annual Global Healthcare Conference and the 44th Annual J.P. Morgan Healthcare Conference showcased its growth prospects. The approval of Sephience in Japan further expanded its market reach.

1.c. Company Highlights

2. PTC Therapeutics' Q3 2025 Earnings: A Strong Launch for Sephience

PTC Therapeutics reported a robust third-quarter 2025 with total revenue reaching $211 million, driven by a strong performance from Emflaza and the successful launch of Sephience, a newly approved treatment for phenylketonuria (PKU). The company's non-GAAP EPS came in at $0.2, significantly beating estimates of -$1.19. The revenue growth was largely attributed to the $19.6 million generated from Sephience, with 521 patient start forms received from US centers. Non-GAAP R&D expenses were $91 million, and non-GAAP SG&A expenses were $74 million, indicating a substantial investment in the launch of Sephience.

Publication Date: Nov -16

📋 Highlights
  • Strong Q3 Revenue: Total revenue reached $211 million, with Sephience contributing $19.6 million in its first quarter as a newly launched PKU treatment.
  • Full-Year Guidance Raised: 2025 revenue outlook narrowed to $750–800 million, driven by Emflaza’s performance and Sephience’s successful launch.
  • Sephience Launch Momentum: Generated $14.4 million in the U.S. and $5.2 million ex-U.S., with 521 patient start forms and 341 patients on therapy (avg. 2–4 weeks from enrollment to treatment).
  • Robust Cash Position: Ended Q3 with $1.68 billion in cash, supporting future growth and R&D, alongside $91 million in non-GAAP R&D expenses.
  • Global Expansion Plans: Anticipating Japanese approval by year-end, with Germany entering a 6-month benefit assessment and Brazil targeting authorization for ~6,000 PKU patients.

Sephience Launch Update

The launch of Sephience has been highly successful, with 341 patients on commercial therapy and a strong response from healthcare providers and patients. The company has seen a rapid and favorable response to Sephience, with over 250 million lives covered by payers and no significant restrictions on access. The safety profile has been excellent, and the once-daily oral administration has been well-received by physicians. Refill dynamics are showing positive momentum, with the vast majority of patients prescribed Sephience in August or early September receiving refills.

Financial Guidance and Outlook

The company has narrowed its full-year guidance to $750-800 million, driven by strong performance from Emflaza and the successful launch of Sephience. Management expects to generate leverage ahead of Street expectations and has a plan to manage OpEx, with a decline expected in 2026. Analysts estimate next year's revenue growth at -46.0%, indicating a potential slowdown in growth.

Valuation Metrics

PTC Therapeutics' current valuation metrics indicate a mixed picture. The P/E Ratio stands at 7.86, while the P/S Ratio is at 3.4. The EV/EBITDA ratio is 6.43, suggesting a relatively reasonable valuation. However, the ROE is significantly negative at -182.66%, and the P/B Ratio is -37.94, indicating potential concerns regarding the company's profitability and book value.

Future Prospects

The company is expecting approval in Japan by year-end and anticipates a premium price for Sephience. Additionally, PTC Therapeutics is working on early access and named patient programs in Europe and expects to receive authorization for Sephience in Brazil this quarter. The company's R&D Day on December 2nd will provide further insights into its research programs, including the registrational trial for Huntington's disease, which has shown proof of target engagement and mechanism of action.

3. NewsRoom

Card image cap

Matthew Klein Sells 7,371 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

Feb -22

Source: defenseworld.net

Card image cap

19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB

Feb -22

Source: defenseworld.net

Card image cap

PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call Transcript

Feb -20

Source: seekingalpha.com

Card image cap

PTC Therapeutics (PTCT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Feb -20

Source: zacks.com

Card image cap

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

Feb -20

Source: zacks.com

Card image cap

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb -19

Source: prnewswire.com

Card image cap

Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Feb -16

Source: zacks.com

Card image cap

PTC Therapeutics Provides Regulatory Update on Translarna™

Feb -12

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.00%)

6. Segments

Small Molecule and Gene Therapeutics

Expected Growth: 4.0%

PTC Therapeutics' Small Molecule and Gene Therapeutics segment growth is driven by increasing adoption of Translarna for Duchenne muscular dystrophy, expansion into new markets, and a strong pipeline of novel therapies. Additionally, strategic partnerships and collaborations are expected to fuel growth, along with increasing investment in research and development to address unmet medical needs.

7. Detailed Products

Translarna

A protein synthesis inhibitor for the treatment of nonsense mutations in genetic disorders

Emflaza

A corticosteroid for the treatment of Duchenne muscular dystrophy

Evrysdi

A survival motor neuron 1 (SMN1) splicing modifier for the treatment of spinal muscular atrophy

Waylivra

A treatment for familial chylomicronemia syndrome, a rare genetic disorder

Gene therapy platform

A platform for the development of gene therapies for rare genetic disorders

8. PTC Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

PTC Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for rare genetic disorders. However, the company's focus on developing novel therapies for unmet medical needs reduces the threat of substitutes.

Bargaining Power Of Customers

PTC Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options for patients with rare genetic disorders.

Bargaining Power Of Suppliers

PTC Therapeutics, Inc. has a moderate bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and manufacturing services. However, the company's strong relationships with suppliers and its diversified supply chain mitigate the risk of supplier concentration.

Threat Of New Entrants

PTC Therapeutics, Inc. has a low threat of new entrants due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development, regulatory approvals, and manufacturing capabilities.

Intensity Of Rivalry

PTC Therapeutics, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company must continually innovate and invest in research and development to stay ahead of its competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -57.92%
Debt Cost 7.07%
Equity Weight 157.92%
Equity Cost 7.07%
WACC 7.07%
Leverage -36.68%

11. Quality Control: PTC Therapeutics, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
PTC Therapeutics

A-Score: 5.8/10

Value: 7.8

Growth: 5.6

Quality: 8.4

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
BioMarin Pharmaceutical

A-Score: 4.8/10

Value: 5.0

Growth: 8.4

Quality: 8.0

Yield: 0.0

Momentum: 1.5

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Rhythm Pharma

A-Score: 4.6/10

Value: 6.0

Growth: 5.1

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Celldex Therapeutics

A-Score: 3.8/10

Value: 6.7

Growth: 3.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.7

Growth: 3.7

Quality: 4.5

Yield: 0.0

Momentum: 2.5

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

70.66$

Current Price

70.66$

Potential

-0.00%

Expected Cash-Flows